NCT01299337View on ClinicalTrials.gov

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

CompletedOBSERVATIONAL

Enrollment

29

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Depression

Interventions

DRUG

T3

Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.

Trial Locations (1)

55904

Mayo Clinic Department of Psychiatry and Psychology, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER